Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

Inclusion criteria

• Age between 18 and 80 years old, and expected survival is longer than 3 months
• Clinically or pathologically diagnosed as primary hepatocellular carcinoma
• Disease progression assessed according to mRECIST criteria after PD-1/L1 antibody treatment
• Child-Pugh score of liver function A/B (< 7)
• At least one lesion is suitable for mRECIST assessment
• Strength score (ECOG): 0-1
• The patient and/or family members agree to join the clinical trial and sign the informed consent form

Exclusion criteria

• Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon
• Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation
• Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10^4 before receiving treatment or do not continue to take antiviral drugs regularly
• Pregnant patients
• Combined with other malignant tumors, or have a history of other malignant tumors within 3 years
• Active autoimmune disease, confirmed immunodeficiency, history of systemic steroid medication
• Severe renal dysfunction: creatinine (Cr) > 2 mg/dL or creatinine clearance (CCr) <30 mL/min, severe heart, lung, brain and other important organ diseases
• History of gastrointestinal bleeding within 3 months
• Unable to cooperate with ablation surgery
• Severe gastroesophageal varices